First copies of Gilead coronavirus drug to start selling in Bangladesh

The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals

pharma
Beximco Pharmaceuticals will sell the generic version Gilead Sciences' antiviral drug.
Bloomberg
1 min read Last Updated : May 22 2020 | 2:18 AM IST
Bangladesh’s Beximco Pharmaceuticals has become the world’s first company to start selling the generic version of Gilead Sciences’ antiviral drug on mounting urgency to treat the infection caused by the coronavirus.
 
The Dhaka-based Beximco, which counts Norges Bank as one of its investors, will sell remdesivir for about 6,000 taka ($71) a vial to private clinics but will give it free to state-run hospitals treating Covid-19 patients, Rabbur Reza, chief operating officer at the company, said in an interview.

AstraZeneca gets order of $1 bn from US         
   
Drug maker AstraZeneca said on Thursday it had secured its first agreements for 400 million doses of a Covid-19 vaccine it is testing, bolstered by an investment from the US vaccine agency. The Anglo-Swedish firm had received more than $1 billion from the US Biomedical Advanced Research and Development Authority for the development, production and delivery of the vaccine. AP/PTI

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusBangladeshPharma Companiesgeneric drugsAstraZeneca

Next Story